![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis’ Cosentyx Gains EU Approval for New Indication
Novartis’ Cosentyx Gains EU Approval for New Indication
April 30, 2020
The European Commission has approved Novartis’ Cosentyx (secukinumab) for adults with active non-radiographic axial spondyloarthritis.
The approval was based on results of a phase 3 trial in which 41.5 percent of patients showed a significant and clinically meaningful reduction in disease activity vs. a placebo.
Cosentyx was originally approved in 2015 as a first-line treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Upcoming Events
-
21Oct